These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16173018)

  • 1. Analysis of cytomegalovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis.
    Boivin G; Goyette N; Gilbert C; Covington E
    J Med Virol; 2005 Nov; 77(3):425-9. PubMed ID: 16173018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
    Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
    Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis.
    Martin M; Goyette N; Ives J; Boivin G
    J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.
    Hantz S; Garnier-Geoffroy F; Mazeron MC; Garrigue I; Merville P; Mengelle C; Rostaing L; Saint Marcoux F; Essig M; Rerolle JP; Cotin S; Germi R; Pillet S; Lebranchu Y; Turlure P; Alain S;
    J Antimicrob Chemother; 2010 Dec; 65(12):2628-40. PubMed ID: 20961907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus.
    Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V
    J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Boutolleau D; Deback C; Bressollette-Bodin C; Varnous S; Dhedin N; Barrou B; Vernant JP; Gandjbakhch I; Imbert-Marcille BM; Agut H
    Antiviral Res; 2009 Feb; 81(2):174-9. PubMed ID: 19063923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
    Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
    J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Analysis of Ganciclovir-Resistant Cytomegalovirus in Renal Transplant Recipients with High Viral Load.
    Sohrabi M; Behzadian F; Hosseini SM; Lashini H
    Arch Iran Med; 2016 Oct; 19(10):700-703. PubMed ID: 27743434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
    Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
    J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
    Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
    J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
    Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
    Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis.
    Boivin G; Goyette N; Farhan M; Ives J; Elston R
    J Clin Virol; 2012 Mar; 53(3):208-13. PubMed ID: 22237003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients.
    Iwasenko JM; Scott GM; Naing Z; Glanville AR; Rawlinson WD
    Transpl Infect Dis; 2011 Apr; 13(2):145-53. PubMed ID: 21070537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
    Fischer L; Sampaio KL; Jahn G; Hamprecht K; Göhring K
    J Clin Virol; 2015 Aug; 69():150-5. PubMed ID: 26209398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose Valganciclovir Treatment for Resistant Cytomegalovirus Colitis due to UL97 and UL54 Mutations.
    Baradhi KM; Aure RL; El-Amm JM
    Transplant Proc; 2018; 50(1):142-144. PubMed ID: 29407298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
    Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
    Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan.
    Yang SL; Lin TW; Lin HC; Wang HY; Chang PY; Wang PN; Yang S; Lu JJ
    J Microbiol Immunol Infect; 2021 Oct; 54(5):971-978. PubMed ID: 33632621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.